CPI Work with AlgiPharma to Scale up Alginate Oligomers
The Centre for Process Innovation Ltd (UK) is leading the scale-up, whereas AlgiPharma AS (Norway) needs the final product as an Active Pharmaceutical Ingredient in its development of medicines for cystic fibrosis, COPD and chronic wounds, like diabetic foot ulcers
The biofilm disrupting and antibiotic potentiating technology that has been developed by AlgiPharma was recently published (Khan S., et al., Antimicrob Agents Chemother. 2012;56(10):5134 – 41) and Powell LC., et al., Biofouling. 2013;29(4):413 – 21).
If the scale-up is successful it will facilitate the introduction of novel medicinal products to the market that will ease patient suffering and potentially reduce healthcare costs. In addition it will be a new tool in fighting multi-drug resistant bacteria. Both AlgiPharma and CPI will obtain help from SINTEF (Norway), in this innovative collaborative effort between Norwegian and English researchers.